drugset / Trial / NCT01797341

Prograf-Advagraf Cross Over Conversion Study

NCT01797341

Phase 3 Completed 13 enrolled University Health Network, Toronto
RandomizedCrossoverOpen-labelTreatment

Summary

The present study is aimed at evaluating the impact of a switch from Prograf to Advagraf on renal function, trough tacrolimus levels, drug-related adverse effects and adherence in stable recipients of kidney-pancreas transplants. MPA pharmacokinetics will also be evaluated. The results of this study have the potential to change current practice.

Timeline

Start
2013-06
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule

Indications

No indication recorded.